At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Mar 17, 2026 at 22:46 ET
SAB Biotherapeutics (SABS) announced the pricing of a public offering, selling 19.3 million shares at $3.85 and pre-funded warrants for 2.8 million shares at $3.8499, raising approximately $85 million in gross proceeds. The funds will primarily support clinical development of its lead candidate, SAB-142, for type 1 diabetes. The offering includes a 30-day underwriter option to purchase up to an additional 3.3 million shares.
- SAB Biotherapeutics is raising approximately $85 million through a public offering of common stock and pre-funded warrants.
- 19,324,677 shares priced at $3.85 per share; pre-funded warrants for 2,753,246 shares priced at $3.8499.
- Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.
- Proceeds will fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access